10-Q: Nutra Pharma Q1 2023: Sales Up, Losses Mount, Going Concern Doubt

Nutra Pharma Corp. reported increased sales in Q1 2023 but faced a significant net loss, substantial debt defaults, and ongoing going concern doubts, despite settling major lawsuits post-period.

Summary

• Net sales to unrelated customers increased by 296% to $54,522 for the three months ended March 31, 2023, compared to $13,759 in the prior year period.
• Net sales to a related party surged by 1,091% to $100,502 for the three months ended March 31, 2023, up from $8,439 in the prior year period.
• Gross profit improved to $103,099, representing a 66.5% margin, for Q1 2023, compared to $7,792 (35.1% margin) for Q1 2022, primarily due to lower manufacturing costs on related party sales.
• Operating expenses increased by $80,104, or 25.33%, to $396,320 for Q1 2023, driven mainly by higher professional fees, particularly legal expenses related to the SEC lawsuit.
• A bad debt expense of $105,465 from a related party was recorded for the three months ended March 31, 2023.
• The company reported a net loss of $592,560 for Q1 2023, a significant decline from a net income of $5,013,462 in Q1 2022, largely due to a swing in the fair value of convertible notes and derivatives from a $5.5 million gain to a $51,871 loss.
• An accumulated deficit of $74,144,678, a working capital deficit of $12,976,943, and a stockholders deficit of $12,970,012 were reported as of March 31, 2023.
• The cash balance remained at $0 at both March 31, 2023, and December 31, 2022.
• Net cash used in operating activities decreased to $92,775 in Q1 2023 from $258,234 in Q1 2022.
• Total liabilities increased to $13,694,893 at March 31, 2023, from $13,132,365 at December 31, 2022.
• The SEC lawsuit was settled on August 28, 2024, with the company ordered to pay $520,940 in disgorgement, $59,295 in prejudgment interest, and a $100,000 civil penalty, totaling $680,235.
• The CSA 8411, LLC lawsuit was settled on May 19, 2025, for $125,000, resulting in a gain on settlement of $53,526.

Sentiment

Score: 2

Explanation: While there was notable revenue growth and a positive regulatory development (Orphan Status for RPI78M), the company's severe financial distress, including a significant net loss, substantial accumulated and working capital deficits, zero cash, and an explicit 'going concern' warning, indicates a very poor overall financial position. The reliance on continuous dilutive financing and related-party loans, coupled with the OTC Expert Market listing, points to extreme operational and investment risk.

Positives

• Net sales to unrelated customers increased by 296% to $54,522 for the three months ended March 31, 2023.
• Net sales to a related party increased by 1,091% to $100,502 for the three months ended March 31, 2023.
• Gross profit margin significantly improved to 66.5% in Q1 2023 from 35.1% in Q1 2022, driven by lower manufacturing costs.
• Net cash used in operating activities decreased substantially from $258,234 in Q1 2022 to $92,775 in Q1 2023.
• The RPI78M drug candidate was granted Orphan Status by the FDA for pediatric Multiple Sclerosis, which offers benefits like shorter approval timelines, fee waivers, rolling review, and fast-track approval.
• The SEC lawsuit, a significant legal overhang, was settled on August 28, 2024, resolving uncertainty.
• The CSA 8411, LLC lawsuit was settled on May 19, 2025, for $125,000, resulting in a gain on settlement of $53,526.

Negatives

• Reported a net loss of $592,560 for the three months ended March 31, 2023, a substantial reversal from a net income of $5,013,462 in the prior year period.
• The change in fair value of convertible notes and derivatives swung from a $5,546,361 gain in Q1 2022 to a $51,871 loss in Q1 2023, significantly impacting net results.
• The company has an accumulated deficit of $74,144,678, a working capital deficit of $12,976,943, and a stockholders deficit of $12,970,012 as of March 31, 2023.
• There is substantial doubt regarding the company's ability to continue as a going concern.
• The company has a significant amount of indebtedness in default.
• The cash balance was $0 at March 31, 2023, indicating severe liquidity issues.
• A bad debt expense of $105,465 from a related party was recorded in Q1 2023.
• The company's common stock is listed on the OTC Market Group's Expert Market, which limits its ability to raise capital.
• Operating expenses increased, primarily due to higher professional fees, including legal expenses.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses, an accumulated deficit, a working capital deficit, and significant indebtedness in default.
• The company's ability to continue operations is contingent upon securing additional financing, increasing ownership equity, and achieving profitable operations, which are uncertain.
• Reliance on debt and equity funding has not been sufficient to execute the business plan.
• The common stock's listing on the OTC Market Group's Expert Market limits capital raising capabilities.
• Uncertainty in successfully developing and commercializing products from research and development activities.
• The company operates in an intensely competitive biotechnology industry.
• Failure to successfully execute planned partnering and out-licensing of products or technologies could adversely affect future performance.
• Economic downturns and credit market crises may adversely affect the ability to obtain financing.
• The biotechnology industry is prone to substantial and potentially rising litigation costs.
• Failure to comply with extensive legal and regulatory requirements in the healthcare industry could lead to increased costs, penalties, and business losses.
• Raising additional equity capital could result in substantial dilution to existing shareholders.
• There is no assurance that additional loans from officers and directors will be secured.
• The 'tainted equity environment' means that convertible debt, options, and warrants are treated as derivative liabilities due to the potential for shares issuable to exceed authorized limits.

Future Outlook

The company plans to re-engage in the regulatory approval process for Nyloxin in Canada in 2026. It also intends to complete human clinical studies comparing Nyloxin Extra Strength to prescription pain relievers, but no timeline is available until adequate financing is secured. A stated goal was to initiate Phase I/II trials for RPI78M in pediatric Multiple Sclerosis in 2022, but the filing does not indicate completion or updated timelines, suggesting a delay or ongoing effort. The company expects to require approximately $600,000 to fund existing operations over the next twelve months and anticipates needing to raise additional equity capital, which could result in substantial dilution, or seek further loans from officers and directors. The Research Services Agreement with StemSation was terminated effective March 31, 2025.

Management Comments

• "Our goal is that with Nyloxin, we can greatly reduce the instances of opiate abuse and overuse of NSAIDS in high risk groups like the US military."
• "We are currently working with consultants to develop trial protocols for a Phase I/II trial for the use of RPI78M in the treatment of Pediatric Multiple Sclerosis. Our goal is to initiate these trials in 2022."
• "As of the date of the filing of this report, we do not believe that our source of cash is adequate for the next 12 months of operation and there is substantial doubt about our ability to continue as a going concern."
• "We expect to utilize the proceeds from these funds and additional capital to manufacture Nyloxin and Pet PainAway and reduce our debt level."
• "There can be no assurance that we will be able to raise sufficient equity capital to fund our working capital requirements on terms acceptable to us, or at all."
• "We may also seek additional loans from our officers and directors; however, there can be no assurance that we will be successful in securing such additional loans."

Industry Context

The company operates in the biotechnology and consumer health sectors, focusing on homeopathic, non-narcotic, non-addictive pain relievers (Nyloxin, Pet PainAway, Equine PainAway, Luxury Feet) as alternatives to traditional opioid and NSAID-based drugs, aligning with growing consumer and regulatory concerns about addiction and side effects. Its drug discovery pipeline includes therapeutic protein products (RPIMN, RPI78M) for severe neurological and autoimmune disorders like HIV and Multiple Sclerosis. The Orphan Status granted to RPI78M for pediatric MS positions it in a specialized market with regulatory advantages. The company's strategy to offer an orally administered biologic for MS, if successful, could be a significant differentiator in the MS drug market, which is currently dominated by injectable treatments.

Comparison to Industry Standards

• The company's focus on non-narcotic, non-addictive pain relievers aligns with a broader industry trend towards safer pain management alternatives, contrasting with the opioid crisis and concerns over NSAID overuse.
• RPI78M's potential as an orally administered biologic for Multiple Sclerosis is a notable innovation, as most biologic MS drugs require injections, potentially offering a significant quality-of-life benefit over competitors.
• The granting of Orphan Status for RPI78M in pediatric Multiple Sclerosis provides regulatory advantages (shorter timelines, fee waivers, fast-track approval) that can accelerate development compared to standard drug approval pathways.
• Financially, the company's recurring significant losses, substantial accumulated deficit ($74.1 million), working capital deficit ($12.9 million), and stockholders deficit ($12.9 million) are far below the typical financial health of established public companies in the biotechnology or consumer health industries.
• The company's reliance on debt and equity funding, coupled with its common stock being on the OTC Market Group's Expert Market, indicates a highly speculative investment profile, significantly below the liquidity and capital access standards of major exchange-listed peers.
• The high number of shares outstanding (over 7 billion) and low stock price ($0.0001) are characteristic of micro-cap or penny stocks, which typically face greater challenges in attracting institutional investment compared to more mature companies in the sector.

Management Changes

Corporate Governance

Legal Proceedings

• **CSA 8411, LLC v. Nutra Pharma Corp. (Case No. CACE 18-023150):** A lawsuit filed on October 12, 2018, to recover $100,000 allegedly owed under an amended promissory note. The case was settled on May 19, 2025, for $125,000, payable as an initial $35,000 payment and nine subsequent monthly payments of $10,000. This settlement resulted in a gain of $53,526.
• **Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus (Case No. 2:18-cv-05459):** A lawsuit filed on September 28, 2018, alleging fraud and violations of federal securities laws. The company, without admitting or denying allegations, settled on August 28, 2024, agreeing to pay $520,940 in disgorgement, $59,295 in prejudgment interest, and a $100,000 civil penalty, totaling $680,235. The settlement also included permanent injunctive relief against the company.

Related Party Transactions

• The company acts as a product formulator and contract manufacturer for Avini Health, which is owned by the company's chief executive officer (Rik Deitsch, as per Note 13, though Michael Flax is the current CEO). These transactions were not conducted at arm's length.
• A portion of the company's space is sublet to Avini Health under a one-year sublease for a monthly rent of $5,000, with the first three months rent-free, commencing May 2022.
• The company owed a director $154,345 in accrued interest at March 31, 2023, stemming from a $200,000 loan borrowed in 2010, which is in default.
• Deferred revenue to a related party amounted to $281,417 at March 31, 2023.
• A net balance of $319,279 was due to Rik Deitsch (former CEO) at March 31, 2023, which is unsecured and accrues interest at 4%.
• Accrued payroll due to officers totaled $1,253,693 at March 31, 2023.
• Net sales to a related party were $100,502 for the three months ended March 31, 2023.
• A bad debt expense of $105,465 from a related party was recorded for the three months ended March 31, 2023.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from potential future equity raises, substantial accumulated deficit, and severe going concern doubts. The common stock's listing on the OTC Expert Market limits liquidity and potential value realization.
• **Creditors:** A significant amount of indebtedness is in default, raising concerns about the company's ability to meet its repayment obligations. Legal settlements require substantial payments, adding to financial strain.
• **Employees/Officers:** Accrued payroll due to officers totaling $1.25 million indicates potential delays or issues with compensation, which could impact morale and retention.
• **Customers:** The continued availability and development of the company's pain relief products (Nyloxin, Pet PainAway, etc.) are directly tied to its ability to secure funding and maintain operational continuity, posing a risk to product supply.
• **Suppliers:** The company's financial instability and reliance on external funding could impact its ability to pay suppliers on time, potentially affecting supply chain relationships.

Next Steps

• Secure additional financing (debt or equity) to fund operations and address liquidity issues.
• Increase ownership equity to improve the balance sheet.
• Attain profitable operations to achieve financial stability and mitigate going concern doubts.
• Increase sales and awareness of pain products through more aggressive marketing efforts.
• Re-engage in the regulatory approval process for Nyloxin in Canada, with an expected timeline of 2026.
• Complete human clinical studies for Nyloxin Extra Strength, contingent on securing adequate financing.
• Initiate Phase I/II trials for RPI78M in pediatric Multiple Sclerosis, a goal that was set for 2022 and is still pending.
• Continue to monitor public health developments and related economic conditions that could affect the business.
• Make scheduled payments for the SEC lawsuit settlement ($680,235 total) and the CSA 8411, LLC lawsuit settlement ($125,000 total).
• Convert the remaining balance of StemSation notes receivable into common stock as per the settlement agreement.
• Amortize debt discounts and issuance costs associated with various new promissory notes and future receipts agreements.

Key Dates

Recommendation

The company exhibits severe financial distress, characterized by a net loss of $592,560 in Q1 2023 (a significant reversal from prior year income), an accumulated deficit exceeding $74 million, and substantial working capital and stockholders deficits. The explicit 'going concern' warning, coupled with a $0 cash balance and a significant amount of debt in default, indicates critical liquidity issues and a high risk of business failure. While sales increased, the underlying operational profitability is weak, and future funding is uncertain and likely to be highly dilutive. The common stock's listing on the OTC Expert Market further limits investor access and liquidity. Despite recent legal settlements resolving some uncertainty, the financial obligations remain substantial. Given these overwhelming negative factors, the stock presents an exceptionally high risk with significant downside potential.

Keywords

Nutra Pharma, ReceptoPharm, biotechnology, pain relief, Nyloxin, Pet PainAway, Equine PainAway, Luxury Feet, Cell Defender, drug discovery, RPIMN, RPI78M, Multiple Sclerosis, HIV, Orphan Status, financial results, net loss, going concern, debt default, legal settlement, SEC lawsuit, convertible notes, OTC Expert Market, SEC 10-Q